Quantcast
Last updated on April 17, 2014 at 21:23 EDT

ResearchMoz: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)

December 12, 2011

ALBANY, New York, December 12, 2011 /PRNewswire/ –

New Report Added in ResearchMoz Reports Database Biosimilar/Follow-on Biologics Market
Report & Forecast: A Focus on the US (2011-2020)
[http://www.researchmoz.com/biosimilar-follow-on-biologics-market-report-and-forecast-a-focus-on-the-us-2011-2020-report.html ]
Published by IMARC
[http://www.researchmoz.com/publisher/imarc-25.html ].

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion
dollar sales potential that most analysts believe they will generate. This market,
however, unlike small molecule generics, is expected to be more akin to a marathon than a
sprint. IMARC Group, one of the world’s leading research and advisory firms, in its new
report “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US
(2011-2020)” finds that biosimilars in the US will soon represent a multi-billion dollar
market as they would be posing stiff competition to as many as twenty biological molecules
during 2011-2020.

Browse the full Report:

http://www.researchmoz.com/biosimilar-follow-on-biologics-market-report-and-forecast-a-focus-on-the-us-2011-2020-report.html

Findings from the report suggest that the historical performance of Omnitrope cannot
be taken as a benchmark to gauge the potential of pipeline biosimilars as market
acceptance for each biosimilar class is expected to vary significantly from one another.
The report expects that the competition between branded biological drugs and their
biosimilar counterparts would be more of a brand-brand competition than a brand-generic
competition. The high costs involved in the development and launch of biosimilars are
expected to limit the number of players in this market. As a result, erosions in price and
volume caused by biosimilars are likely to be lower compared to those created by small
molecule generics.

IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market
[http://www.researchmoz.com/biosimilar-follow-on-biologics-market-report-and-forecast-a-focus-on-the-us-2011-2020-report.html ]
Report & Forecast: A Focus on the US (2011-2020)”
provides an analytical and statistical insight into the US biosimilar market. The study,
that has been undertaken using desk-based as well as qualitative primary research,
provides and draws upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:

        - Identification of currently marketed biosimilars and their historical
          performance
        - Identifying the reasons for the slow uptake of currently marketed biosimilars
        - Analyzing historical data to formulate conclusions on the future growth and
          market trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:

        - Analyzing historical time series data on price, volume and sales erosion
          in the US & Europe
        - Analyzing previous models and assumptions on price and volume erosion caused
          by biosimilars
        - Evaluating and comparing price and volume erosion created by biosimilars
          vis-a-vis by small molecule generics
        - Evaluating and comparing price, volume and sales erosion by biosimilars across
          various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules: Molecules
Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex),
Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin
Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon
Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab
(Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel),
Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair)
and Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:

        - Historical background and overview
        - Historical brand sales
        - Patent position
        - Competing products
        - Biosimilars in pipeline
        - Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders
and Growth Deficiency

Focus of the Analysis for Each Indication:

        - Historical brand sales
        - Brand and biosimilar sales forecasts
        - Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:

        - Identifying branded biological manufacturers that expect the highest
          amount of erosion from biosimilars
        - Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:

        - An insight into the Biologics Price Competition and Innovation Act
        - An insight into the key biosimilar issues that still remain unaddressed
        - Interchangeability and Substitutability
        - Data Exclusivity
        - Statutory provisions for dealing with patent litigations

Browse All Biotechnology Market
[http://www.researchmoz.com/biotechnology-market-reports-30.html ] Research Reports &
Industry Analysis

Related Reports

Generic Growth Strategies – Manufacturers to Increase Focus on Super Generics and
Biosimilars to Drive Revenues
[http://www.researchmoz.com/generic-growth-strategies-manufacturers-to-increase-focus-on-super-generics-and-biosimilars-to-drive-revenues-report.html ]

Cancer Supportive Care Products Market to 2016 – Market is Expected to Decline after
2014 Due to Generic Erosion and Entry of Biosimilars
[http://www.researchmoz.com/cancer-supportive-care-products-market-to-2016-market-is-expected-to-decline-after-2014-due-to-generic-erosion-and-entry-of-biosimilars-report.html ]

Biosimilars Approval Pathways in the US and Europe – Development and Approval of
Biosimilar mABs May Face Tough Regulatory Environment
[http://www.researchmoz.com/biosimilars-approval-pathways-in-the-us-and-europe-development-and-approval-of-biosimilar-mabs-may-face-tough-regulatory-environment-report.html ]

Biotechnology Industry 2010 Yearbook – Top Biologics, Biosimilars, Licensing and
Financing, Mergers and Acquisitions
[http://www.researchmoz.com/biotechnology-industry-2010-yearbook-top-biologics-biosimilars-licensing-and-financing-mergers-and-acquisitions-report.html ]

Oxygen Concentrator Market
[http://www.researchmoz.com/oxygen-concentrator-market-shares-strategies-and-forecasts-worldwide-2011-to-2017-report.html ]

Application Server Market
[http://www.researchmoz.com/application-server-market-shares-strategies-and-forecasts-worldwide-2011-to-2017-report.html ]

Digital Dentistry Market
[http://www.researchmoz.com/digital-dentistry-market-shares-strategies-and-forecasts-worldwide-2011-to-2017-report.html ]

About Us

ResearchMoz is the one stop online destination to find and buy market research reports
[http://www.researchmoz.com ]. We fulfill all your research needs spanning across industry
verticals with our huge collection of market research reports. We provide our services to
all sizes of organizations and across all industry verticals and markets. Our Research
Coordinators have in-depth knowledge of reports as well as publishers and will assist you
in making an informed decision by giving you unbiased and deep insights on which reports
will satisfy your needs at the best price.

        Contact
        M/s Sheela
        90 Sate Street, Suite 700
        Albany, NY 12207
        Tel: +1-518-618-1030
        USA - Canada Toll Free: +1-866-997-4948
        Email: sales@researchmoz.com

http://www.researchmoz.com

        Baby Food Market [http://www.babyfoodmarket.org  ]

http://www.findmarketresearch.org

SOURCE ResearchMoz


Source: PR Newswire